Related Experiment Video
Updated: May 29, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
The human epidermal growth factor receptor 2 (HER2).
Laura J Tafe1, Gregory J Tsongalis
1Department of Pathology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Laura.J.Tafe@hitchcock.org
The human epidermal growth factor receptor 2 (HER2) is a key target in cancer therapy. Novel treatments, including monoclonal antibodies and small molecule drugs, target HER2, advancing personalized medicine.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The "war on cancer" initiative spurred the development of targeted cancer therapies.
- The human epidermal growth factor receptor 2 (HER2) gene has emerged as a significant target for novel therapeutics.
- HER2-targeted therapies represent a paradigm shift in cancer treatment strategies.
Purpose of the Study:
- To review the biological functions of HER2.
- To discuss the clinical applications of HER2 as a biomarker.
- To explore HER2 as a therapeutic target in cancer treatment.
Main Methods:
- Review of scientific literature on HER2 biology and clinical applications.
- Analysis of HER2's role in personalized medicine and companion diagnostics.
- Examination of therapeutic strategies targeting HER2.
Main Results:
- HER2 is a crucial biomarker for disease identification and prognosis.
- Targeting HER2 involves both extracellular monoclonal antibody therapy and intracellular small molecule drugs.
- HER2-targeted therapies exemplify early applications of personalized medicine.
Conclusions:
- HER2 is a validated therapeutic target with significant clinical impact.
- The development of HER2-targeted therapies has advanced personalized cancer care.
- Understanding HER2 biology is critical for developing future cancer treatments.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Receptor Tyrosine Kinases
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

